Thus, pharmacological inhibition of Hsp90 is a promising avenue to improve the clinical outcomes of patients with PAH, and drugs that target Hsp90 in mitochondria will show more advantages in PAH treatment (Boucherat et al., 2018). This evidence concerns the gene HSP90AB1 and pulmonary arterial hypertension.